Reparixin
As of the edition of 20 October 2026, Reparixin is a small molecule: stopped in 2024; acts on CXCR1 and CXCR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 14, 5 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Infections; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Reparixin.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 8 | 4 | 1 | 3 |
| Phase 3 | 5 | 3 | 0 | 2 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Dompé Farmaceutici | Lead sponsor of trials | 2005 to now |